MA40605A - Composé pyrazolothiazole et médicament - Google Patents
Composé pyrazolothiazole et médicamentInfo
- Publication number
- MA40605A MA40605A MA040605A MA40605A MA40605A MA 40605 A MA40605 A MA 40605A MA 040605 A MA040605 A MA 040605A MA 40605 A MA40605 A MA 40605A MA 40605 A MA40605 A MA 40605A
- Authority
- MA
- Morocco
- Prior art keywords
- present
- jak1
- medication
- compounds
- compound
- Prior art date
Links
- -1 PYRAZOLOTHIAZOLE COMPOUND Chemical class 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 101150079478 jak1 gene Proteins 0.000 abstract 3
- VHHWHDFVZGPKRT-UHFFFAOYSA-N 5h-pyrazolo[3,4-d][1,3]thiazole Chemical class N1=NC2=NCSC2=C1 VHHWHDFVZGPKRT-UHFFFAOYSA-N 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'objectif de la présente invention est de fournir un composé ayant un effet inhibiteur exceptionnel de jak1. Des exemples de la présente invention comprennent des composés pyrazolothiazole représentés par la formule générale [i], ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Les composés de la présente invention ont une activité inhibitrice de jak1. étant donné cette activité inhibitrice jak1, les composés de la présente invention ont également un effet immunosuppresseur (contre, par exem
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014177969 | 2014-09-02 | ||
| PCT/JP2015/074935 WO2016035814A1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40605A true MA40605A (fr) | 2017-07-12 |
| MA40605B1 MA40605B1 (fr) | 2020-10-28 |
Family
ID=55439874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40605A MA40605B1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9937176B2 (fr) |
| EP (1) | EP3190116B1 (fr) |
| JP (1) | JP6558372B2 (fr) |
| KR (1) | KR102294330B1 (fr) |
| CN (1) | CN107108653B (fr) |
| AU (1) | AU2015312886B2 (fr) |
| BR (1) | BR112017003800B1 (fr) |
| CA (1) | CA2959721C (fr) |
| CL (1) | CL2017000478A1 (fr) |
| CO (1) | CO2017002982A2 (fr) |
| CY (1) | CY1123320T1 (fr) |
| DK (1) | DK3190116T3 (fr) |
| ES (1) | ES2827243T3 (fr) |
| HR (1) | HRP20201382T1 (fr) |
| HU (1) | HUE050565T2 (fr) |
| IL (1) | IL250729B (fr) |
| LT (1) | LT3190116T (fr) |
| MA (1) | MA40605B1 (fr) |
| MX (1) | MX377926B (fr) |
| MY (1) | MY181814A (fr) |
| NZ (1) | NZ729494A (fr) |
| PE (1) | PE20170668A1 (fr) |
| PH (1) | PH12017500383B1 (fr) |
| PL (1) | PL3190116T3 (fr) |
| PT (1) | PT3190116T (fr) |
| RS (1) | RS60798B1 (fr) |
| RU (1) | RU2688660C2 (fr) |
| SG (2) | SG11201701447UA (fr) |
| SI (1) | SI3190116T1 (fr) |
| SM (1) | SMT202000503T1 (fr) |
| TW (1) | TWI679205B (fr) |
| UA (1) | UA121869C2 (fr) |
| WO (1) | WO2016035814A1 (fr) |
| ZA (1) | ZA201701492B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| CN110709346B (zh) | 2017-06-09 | 2020-12-22 | 三菱电机株式会社 | 乘客输送机 |
| EP4081199A4 (fr) * | 2019-12-23 | 2024-01-17 | SRI International | Inhibiteurs de lipoxygénase |
| JP7742516B1 (ja) * | 2025-07-31 | 2025-09-19 | 日本新薬株式会社 | 好酸球性多発血管炎性肉芽腫症の処置剤 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
| US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
| GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| BRPI0510340A (pt) | 2004-04-28 | 2007-10-30 | Pfizer | derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina |
| NZ567133A (en) * | 2005-09-30 | 2011-07-29 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| MY167260A (en) * | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| ES2396126T3 (es) * | 2008-04-15 | 2013-02-19 | Eisai R&D Management Co., Ltd. | Compuesto de 3-fenilpirazol[5,1-b]tiazol |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| EP2373664B1 (fr) * | 2008-12-19 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Pyrazoles bicycliques en tant qu'inhibiteurs de protéines kinases |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JP5739446B2 (ja) | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| EP2338888A1 (fr) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| KR20140015162A (ko) | 2010-01-12 | 2014-02-06 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| WO2012022045A1 (fr) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Composés pyrrolopyrimidiniques et leurs utilisations |
| EP2616443A1 (fr) | 2010-09-14 | 2013-07-24 | Exelixis, Inc. | Dérivés de la phtalazine comme inhibiteurs de jak1 |
| WO2012054364A2 (fr) | 2010-10-22 | 2012-04-26 | Merck Sharp & Dohme Corp. | Diamines bicycliques utiles en tant qu'inhibiteurs des kinases janus |
| WO2012085176A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Composés pyrazinones tricycliques, leurs compositions et leurs procédés d'utilisation en tant qu'inhibiteurs de janus kinase |
| WO2013025628A1 (fr) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Composés et procédés d'inhibition de janus kinase |
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/zh active
- 2015-09-02 MA MA40605A patent/MA40605B1/fr unknown
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 PL PL15838466T patent/PL3190116T3/pl unknown
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/lt unknown
- 2015-09-02 MX MX2017002488A patent/MX377926B/es unknown
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/ko active Active
- 2015-09-02 CA CA2959721A patent/CA2959721C/fr active Active
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/hu unknown
- 2015-09-02 SM SM20200503T patent/SMT202000503T1/it unknown
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/ru active
- 2015-09-02 HR HRP20201382TT patent/HRP20201382T1/hr unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/pt active IP Right Grant
- 2015-09-02 ES ES15838466T patent/ES2827243T3/es active Active
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/ja active Active
- 2015-09-02 PT PT158384669T patent/PT3190116T/pt unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/sl unknown
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/zh active Active
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/da active
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/es unknown
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/fr active Active
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/fr not_active Ceased
- 2015-09-02 RS RS20201081A patent/RS60798B1/sr unknown
- 2015-09-02 UA UAA201702990A patent/UA121869C2/uk unknown
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/es unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/es unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502171A1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| MA46337A (fr) | Composé de pyridine | |
| MA58087B1 (fr) | Nouveaux dérivés de méthylquinazolinone | |
| MA33330B1 (fr) | Quinazolines substituées comme fongicides | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MA38039A1 (fr) | Composés de céphem substitués en position 2 | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| MA40605A (fr) | Composé pyrazolothiazole et médicament | |
| MA34385B1 (fr) | Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes) | |
| MY196572A (en) | Amino-Methyl Piperidine Derivative as Kinase Inhibitor | |
| MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| MX2019012640A (es) | Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa. | |
| MA30664B1 (fr) | Derive d'aminoalcool et immunodepresseur le contenant en tant que principe actif. | |
| WO2020251871A3 (fr) | Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
| MX2019011558A (es) | Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| WO2014062852A3 (fr) | Dérivés de thiohydantoïnes et leurs utilisations | |
| MA38991A1 (fr) | Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt |